TME Pharma N.V. announced to preserve financial resources, ongoing financing and partnering activities will be pursued by CEO Aram Mangasarian, long-standing members of staff Senior Vice President of Finance, Heike Balzer, and Vice President Legal and General Counsel, Karen Ophoff, as well as newly appointed Senior Director Investor Relations and Business Development, Ewelina Staniuk. Ewelina assumes the new position after serving as Director Corporate and Business Development since November 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1666 EUR | -5.23% |
|
-26.12% | -27.57% |
19/06 | TME Pharma: in the red, a broker cuts its target | CF |
19/06 | TME PHARMA : Invest Securities reduces its target | CF |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.57% | 5.09M | |
+34.01% | 51.07B | |
+33.84% | 38.61B | |
-8.02% | 38.78B | |
-8.98% | 27.32B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- ALTME Stock
- News TME Pharma N.V.
- TME Pharma N.V. Announces Executive Changes